Cargando…
Hyperhydration with cisplatin does not influence pemetrexed exposure
Pemetrexed is a cytotoxic drug for first‐line treatment of lung cancer. It is often combined with other anticancer drugs such as cisplatin or carboplatin. In clinical practice, hyperhydration regimens are applied to overcome cisplatin‐related nephrotoxicity. As pemetrexed is almost completely elimin...
Autores principales: | de Rouw, Nikki, Derijks, Hieronymus J., Hilbrands, Luuk B., Boosman, René J., Piet, Berber, Koolen, Stijn L. W., Burgers, Jacobus A., Dingemans, Anne‐Marie C., van den Heuvel, Michel M., Hendriks, Lizza E. L., Aerts, Joachim G. J. V., Croes, Sander, Mathijssen, Ron H. J., Huitema, Alwin D. R., Burger, David M., Biesma, Bonne, ter Heine, Rob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290918/ https://www.ncbi.nlm.nih.gov/pubmed/34374116 http://dx.doi.org/10.1111/bcp.15031 |
Ejemplares similares
-
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
por: de Rouw, Nikki, et al.
Publicado: (2022) -
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
por: de Rouw, Nikki, et al.
Publicado: (2021) -
A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions
por: de Rouw, Nikki, et al.
Publicado: (2019) -
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
por: de Rouw, Nikki, et al.
Publicado: (2022) -
Highly sensitive quantification of pemetrexed in human plasma using UPLC‐MS/MS to support microdosing studies
por: van Ewijk‐Beneken Kolmer, Eleonora W. J., et al.
Publicado: (2021)